Ugur Eskiocak

About Ugur Eskiocak

Ugur Eskiocak, With an exceptional h-index of 21 and a recent h-index of 16 (since 2020), a distinguished researcher at University of Texas Southwestern Medical Center,

His recent articles reflect a diverse array of research interests and contributions to the field:

Cd137 antibodies and pd-1 antagonists and uses thereof

CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

Masked il-15 cytokines and their cleavage products

Agonist antibodies that bind human CD137 and uses thereof

Masked il-12 cytokines and their cleavage products

Masked il-2 cytokines and their cleavage products

Tumor-specific cleavable linkers

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Ugur Eskiocak Information

University

Position

___

Citations(all)

1496

Citations(since 2020)

866

Cited By

942

hIndex(all)

21

hIndex(since 2020)

16

i10Index(all)

24

i10Index(since 2020)

21

Email

University Profile Page

Google Scholar

Top articles of Ugur Eskiocak

Cd137 antibodies and pd-1 antagonists and uses thereof

2024/1/4

CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

2023/12/26

Masked il-15 cytokines and their cleavage products

2023/10/19

Agonist antibodies that bind human CD137 and uses thereof

2023/9/12

Masked il-12 cytokines and their cleavage products

2023/5/25

Masked il-2 cytokines and their cleavage products

2023/5/18

Tumor-specific cleavable linkers

2023/3/9

XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Journal for Immunotherapy of Cancer

2023

Abstract B04: Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors

Cancer Immunology Research

2022/12/1

1121 Tigilanol tiglate is a naturally occurring small molecule oncolytic that effectively ablates tumors via intratumoural injection and can enhance response to immune …

2022/11/1

Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer

2022/10/27

Combination of ctla4 and pd1/pdl1 antibodies for treating cancer

2022/9/29

MULTISPECIFIC BINDING CONSTRUCTS DIRECTED AGAINST CHECKPOINT MOLECULES AND ASSOCIATED USES

2022/8/3

Preclinical activity and safety profile of JANX007, a novel PSMA-targeting tumor-activated T cell engager for treatment of metastatic castration-resistant prostate cancer

18th Annual PEGS Boston Conference

2022/5/2

Multispecific binding constructs against checkpoint molecules and uses thereof

2021/9/16

Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos

2021/8/31

Interpretable deep learning uncovers cellular properties in label-free live cell images that are predictive of highly metastatic melanoma

Cell systems

2021/7/21

Anticuerpos agonistas que se unen a cd137 humano y sus usos

2020/4/24

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity

JCI insight

2020/3/3

See List of Professors in Ugur Eskiocak University(University of Texas Southwestern Medical Center)